YM022  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:5mg 25mg in glass bottle
产品描述:基本信息 产品编号:Y10035 产品名称:YM022 CAS: 145084-28-2   储存条件 粉末 -20℃ 四年     分子式: C32H28N4O3 溶于液体 -80℃ 六个月 分子量: 516.59 -20℃ 一个月 化学名:      Solubility (25°C)   体外 DMSO   Ethanol   Water   体内(现配现用)     <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 1.9358mL 9.6789mL 19.3577mL 5mM 0.3872mL 1.9358mL 3.8715mL 10mM 0.1936mL 0.9679mL 1.9358mL   生物活性 产品描述 一种高效,选择性和口服活性胃泌素/胆囊收缩素(CCK)-B 受体 (CCK-BR) 拮抗剂。YM022 显示CCK-B 和 CCK-A 受体的 Ki 值分别为 68pM 和 63nM。YM022 在体内可以抑制胃泌素诱导的胃酸分泌和组氨酸脱羧酶的活化。 靶点/IC50 CCR2 68pM (Ki) CCR1 63nM (Ki)   体外研究 YM022 inhibits binding to canine pancreas CCK-A receptor in a dose-dependent manner,with an IC50 value for [3H]devazepide binding of 136nM.YM022 inhibits the binding of [125I]CCK-8 to canine cloned gastrin/CCK-B receptor in a dose-dependent manner,with an IC50 value for [125I]CCK-8 binding of 0.73nM.Selectivity [ratio of (IC50 for gastrin/CCK-B receptor)/(IC50for CCK-A receptor)] of YM022 is 186. 体内研究 YM022 (intravenous injection;0.01-1μM/kg) dose-dependently inhibits pentagastrin-and peptone meal-induced acid secretion with ED50 values of 0.0261 and 0.0654μmol/kg,respectively,without affecting histamine- or methacholineinduced acid secretion.YM022 (subcutaneous injection;300μmol/kg;single dose) lowers the oxyntic mucosal HDC activity and raises the serum gastrin concentration in a dose-dependent manner (measured 24h after dosage).Maximum enzyme inhibition is achieved at a dose of 300μmol/kg for YM022 and the inhibition of HDC lasts for 4 weeks.At sacrifice,drug residues can be seen at the injection site for as long as 4 (YM022) weeks after injection in rat.YM022 is suspended in 2% Methocel for oral ingestion and in PEG300 for subcutaneous injection. Animal Model: Rat Dosage: 300μmol/kg Administration: Subcutaneous injection;300μmol/kg;single dose Result: Suppressed the ECL cell activity for at least 4 as manifested in greatly reduced HDC activity, greatly elevated serum gastrin level.
保存条件:-20℃